Live Earnings Conference Call: Phathom Pharmaceuticals will host a live Q1 2025 earnings call on May 1, 2025 at 8:00AM ET. Follow this link to get details and listen to Phathom Pharmaceuticals' Q1 2025 earnings call when it goes live. Get details. Phathom Pharmaceuticals (PHAT) Competitors $4.29 -0.07 (-1.61%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT vs. DYN, AUPH, SNDX, BGM, ADPT, IOVA, WVE, ETNB, COLL, and MLYSShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include Dyne Therapeutics (DYN), Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), Qilian International Holding Group (BGM), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Wave Life Sciences (WVE), 89bio (ETNB), Collegium Pharmaceutical (COLL), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. Dyne Therapeutics Aurinia Pharmaceuticals Syndax Pharmaceuticals Qilian International Holding Group Adaptive Biotechnologies Iovance Biotherapeutics Wave Life Sciences 89bio Collegium Pharmaceutical Mineralys Therapeutics Dyne Therapeutics (NASDAQ:DYN) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings. Does the media favor DYN or PHAT? In the previous week, Dyne Therapeutics had 3 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 11 mentions for Dyne Therapeutics and 8 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.02 beat Dyne Therapeutics' score of 0.72 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, DYN or PHAT? Phathom Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$235.94M-$3.35-3.52Phathom Pharmaceuticals$55.25M5.41-$201.59M-$5.35-0.80 Which has more volatility & risk, DYN or PHAT? Dyne Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Is DYN or PHAT more profitable? Dyne Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -57.46% -51.62% Phathom Pharmaceuticals -1,292.14%N/A -79.57% Do analysts recommend DYN or PHAT? Dyne Therapeutics presently has a consensus target price of $47.46, suggesting a potential upside of 302.56%. Phathom Pharmaceuticals has a consensus target price of $21.83, suggesting a potential upside of 408.94%. Given Phathom Pharmaceuticals' higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Dyne Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.07Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of DYN or PHAT? 96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 20.8% of Dyne Therapeutics shares are owned by insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in DYN or PHAT? Phathom Pharmaceuticals received 54 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 77.19% of users gave Dyne Therapeutics an outperform vote while only 72.59% of users gave Phathom Pharmaceuticals an outperform vote. CompanyUnderperformOutperformDyne TherapeuticsOutperform Votes4477.19% Underperform Votes1322.81% Phathom PharmaceuticalsOutperform Votes9872.59% Underperform Votes3727.41% SummaryDyne Therapeutics and Phathom Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$298.79M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-0.757.4522.4218.48Price / Sales5.41242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book-3.386.516.774.25Net Income-$201.59M$143.21M$3.22B$248.23M7 Day Performance6.72%3.97%3.26%3.29%1 Month Performance-35.00%0.37%0.02%2.42%1 Year Performance-52.49%2.60%18.01%5.54% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals4.0385 of 5 stars$4.29-1.6%$21.83+408.9%-52.5%$298.79M$55.25M-0.75110Positive NewsDYNDyne Therapeutics3.3338 of 5 stars$9.33+14.2%$47.46+408.7%-53.4%$1.06BN/A-2.62100Short Interest ↑High Trading VolumeAUPHAurinia Pharmaceuticals2.633 of 5 stars$7.66-1.2%$11.50+50.1%+61.9%$1.05B$235.13M-51.06300Positive NewsSNDXSyndax Pharmaceuticals3.6294 of 5 stars$11.93+3.4%$36.20+203.4%-33.0%$1.03B$23.68M-3.29110Upcoming EarningsPositive NewsBGMQilian International Holding GroupN/A$10.52-4.4%N/AN/A$1.02B$25.10M0.00298ADPTAdaptive Biotechnologies4.1493 of 5 stars$6.83-6.8%$9.40+37.6%+180.9%$1.01B$178.96M-6.27790News CoveragePositive NewsGap DownIOVAIovance Biotherapeutics4.5549 of 5 stars$3.08+0.7%$18.22+491.6%-69.5%$1.01B$164.07M-2.07500Upcoming EarningsGap DownWVEWave Life Sciences4.313 of 5 stars$6.12+3.4%$22.18+262.4%+56.6%$939.33M$108.30M-5.51240Upcoming EarningsAnalyst ForecastPositive NewsETNB89bio2.7852 of 5 stars$6.27+3.5%$27.56+339.5%-5.8%$915.32MN/A-2.1540Upcoming EarningsPositive NewsCOLLCollegium Pharmaceutical4.051 of 5 stars$26.91-0.4%$43.60+62.0%-26.9%$864.67M$631.45M11.60210Upcoming EarningsPositive NewsMLYSMineralys Therapeutics2.3896 of 5 stars$13.24-0.8%$33.00+149.2%+16.0%$858.96MN/A-3.6428Upcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies Dyne Therapeutics Alternatives Aurinia Pharmaceuticals Alternatives Syndax Pharmaceuticals Alternatives Qilian International Holding Group Alternatives Adaptive Biotechnologies Alternatives Iovance Biotherapeutics Alternatives Wave Life Sciences Alternatives 89bio Alternatives Collegium Pharmaceutical Alternatives Mineralys Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHAT Stock Free PHAT Stock Alerts